What is the recommended first‑line treatment for bacterial vaginosis in adult women?

Treatment of Bacterial Vaginosis

First-Line Treatment Recommendation

Prescribe oral metronidazole 500 mg twice daily for 7 days as the preferred first-line treatment for bacterial vaginosis in non-pregnant women. 1, 2, 3

This regimen achieves the highest cure rate (approximately 95%) compared to all other available options and is endorsed by the CDC as the standard of care. 1

---

Alternative First-Line Regimens (Equivalent Efficacy)

If oral therapy is not suitable, the following topical options are equally acceptable first-line choices: 1, 2, 3

• Metronidazole gel 0.75%: One full applicator (5 g) intravaginally once daily for 5 days

  • Cure rate: 70–84% 1, 2
  • Produces serum concentrations <2% of oral dosing, minimizing systemic side effects (nausea, metallic taste) 1
  • No alcohol restriction required with topical formulation due to minimal systemic absorption 1

• Clindamycin cream 2%: One full applicator (5 g) intravaginally at bedtime for 7 days

  • Cure rate: 82–86% 1, 2
  • Critical warning: Oil-based formulation weakens latex condoms and diaphragms; counsel patients to use alternative contraception during treatment and for several days after 1, 2, 3

---

Alternative Regimens (Lower Efficacy—Use Only When Necessary)

• Metronidazole 2 g orally as a single dose: Cure rate 84% (inferior to 7-day regimen); reserve for patients with severe adherence concerns 1, 2, 3

• Clindamycin 300 mg orally twice daily for 7 days: Cure rate 93.9%; appropriate when oral therapy is preferred over topical agents 1, 2

---

Critical Patient Counseling

For Oral Metronidazole

Patients must avoid ALL alcohol (including mouthwash and over-the-counter products containing alcohol) during treatment and for 24 hours after the final dose to prevent disulfiram-like reactions (flushing, nausea, vomiting, tachycardia). 1, 2, 3

For Clindamycin Cream

Warn patients that the oil-based formulation compromises latex barrier contraception; alternative contraception is required during treatment and for several days afterward. 1, 2, 3

---

Treatment in Pregnancy

First Trimester

• Clindamycin vaginal cream 2% is the ONLY recommended treatment, as metronidazole is contraindicated in the first trimester. 1

Second and Third Trimesters

• Metronidazole 250 mg orally three times daily for 7 days is the preferred regimen for symptomatic disease. 1, 2, 3
• High-risk pregnant women (prior preterm delivery) should receive treatment even if asymptomatic, as BV increases risk of premature rupture of membranes, preterm labor, and preterm birth. 2, 3
• Metronidazole is not teratogenic in humans; recent meta-analyses confirm its safety for fetal exposure. 1

---

Special Clinical Scenarios

Pre-Surgical Abortion or High-Risk Gynecologic Procedures

All women with BV (symptomatic or asymptomatic) must be treated before surgical abortion because metronidazole substantially reduces post-abortion pelvic inflammatory disease by 10–75%. 1, 2, 3

Consider treatment before other high-risk procedures (hysterectomy, endometrial biopsy, hysterosalpingography, IUD placement, cesarean section, uterine curettage), as BV is associated with endometritis, PID, and vaginal cuff cellulitis. 1, 3

Asymptomatic BV in Non-Pregnant Women

Do NOT treat asymptomatic BV unless the patient is undergoing surgical abortion or high-risk invasive gynecologic procedures. 1, 2

---

Recurrent Bacterial Vaginosis

For recurrent disease (≥50% of women experience recurrence within 1 year): 2, 4

1. Initial treatment: Metronidazole 500 mg orally twice daily for 10–14 days (extended course) 2

2. If ineffective, initiate suppressive therapy: Metronidazole gel 0.75% intravaginally twice weekly for 3–6 months, which reduces recurrence rates from approximately 60% to 25% 2

---

Partner Management

Do NOT treat male sexual partners. Multiple randomized controlled trials demonstrate that partner treatment does not improve cure rates, reduce recurrence, or affect therapeutic response in women. 1, 2, 3

Symptom flares after intercourse are attributed to local vaginal pH disruption from seminal fluid, not reinfection from the partner. 1

---

Follow-Up Recommendations

Routine follow-up visits are unnecessary if symptoms resolve completely. 1, 2, 3

Patients should return only if symptoms persist or recur. 1

---

Common Clinical Pitfalls to Avoid

• Do NOT prescribe metronidazole gel to patients with confirmed metronidazole allergy—topical use can still trigger systemic reactions; use clindamycin cream instead. 1

• Do NOT use single-dose metronidazole 2 g as first-line therapy—its 84% cure rate is inferior to the 95% cure rate of the 7-day regimen. 1, 2

• Do NOT treat asymptomatic BV in non-pregnant women unless they are undergoing surgical abortion or high-risk procedures—this represents overtreatment and unnecessary antibiotic exposure. 1, 2

• Do NOT use clindamycin vaginal cream in the second/third trimester of pregnancy—it is associated with increased risk of prematurity and neonatal infections. 1

• Do NOT treat sexual partners—this does not reduce recurrence or improve outcomes. 1, 2, 3